Tilray: Fourth Quarter Consensus Estimates

Tilray (TSX: TLRY) (NASDAQ: TLRY) will be reporting its fourth quarter financial results on July 28 before the market opens. Analysts have a consensus $17.77 12-month price target on the company, via a total of 20 analysts, with 2 analysts having strong buy ratings. 3 analysts meanwhile have buy ratings, 14 have hold ratings and a single analyst has a sell rating on the company. The street high comes from Roth Capital with a $25 price target, and the lowest target sits at $1.27 from GLJ Research.

10 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 10 analysts is $146.19 million; this number has been revised upwards from $71.20 million at the start of the year. The highest revenue estimate is $175.4 million, while the lowest is $107.62 million.

Onto EBITDA estimates, there are currently 7 analysts who have fourth-quarter EBITDA estimates. The mean is currently $5.81 million, with this number being flat since the start of the year. The street high estimate currently sits at $11.7 million in EBITDA and the lowest is -$2.83 million.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Gold Is Being Treated Differently This Time | Martino De Ciccio – Montage Gold

The Smart Money is Doubling Down | Fokus Mining & Gold Candle

The Silver Story That Could Surprise the Market | Dan Earle – Highlander Silver

Recommended

Goliath Resources Sees 13% Grade Boost As Stifel Draws Parallels To Great Bear

First Majestic Q4 2025: Record Revenue, Earnings, Annual Silver Output

Related News

Aphria Reports Net Revenues of $152.2 Million, Loss of $98.8 Million in Fourth Quarter 2020

Aphria Inc (TSX: APHA) (NASDAQ: APHA) reported its fourth quarter and full fiscal year financial...

Wednesday, July 29, 2020, 08:35:10 AM

Canadian Cannabis: Canaccord Lifts Cronos Target, Reiterates Canopy Growth And Tilray Ratings

Yesterday Canaccord Genuity Capital Markets put out a second-quarter preview note on the top Canadian...

Thursday, July 28, 2022, 03:02:00 PM

Tilray & Aphria: The Analyst Perspective

This morning it was announced that Aphria Inc (TSX: APHA) (NASDAQ: APHA) and Tilray Inc...

Wednesday, December 16, 2020, 02:04:02 PM

Aurora Cannabis: Seven Analysts Slash Price Targets In Wake Of Blowout Fourth Quarter

Earlier this week, Aurora Cannabis (TSX: ACB) (NYSE: ACB) reported their fourth-quarter financials, after having...

Thursday, September 24, 2020, 11:33:00 AM

Mind Medicine: Canaccord Maintains Ratings Following Financial Results

On Friday, November 13th, Mind Medicine (NEO: MMED) reported their third quarter 2020 financial results....

Tuesday, November 17, 2020, 10:17:00 AM